The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
Donald Patrick
Consultant or Advisory Role - Amgen
Charles S. Cleeland
Consultant or Advisory Role - Amgen
Lesley Fallowfield
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Matthew Raymond Smith
Consultant or Advisory Role - Amgen
Laurence Klotz
Honoraria - Amgen (I); Ferring; Janssen-Ortho; Sanofi
Research Funding - Ferring
Stephane Oudard
Consultant or Advisory Role - Bayer; Janssen; Novartis; Pfizer; Sanofi ; Takeda
Honoraria - Bayer; Janssen; Novartis; Pfizer; Sanofi ; Takeda
Gavin M. Marx
Consultant or Advisory Role - Amgen; Sanofi
Honoraria - Amgen; Sanofi
Research Funding - Amgen
Rachel Wei
Stock Ownership - Amgen
Research Funding - Amgen
Katarina Ohrling
Stock Ownership - Amgen
Research Funding - Amgen
Yi Qian
Stock Ownership - Amgen
Research Funding - Amgen